Skip to content
Biotech Intelligence

Company Intelligence

RemeGen

荣昌生物

HK: 9995 / SH: 688331Yantai, Shandong, ChinaFounded 2008
BIOSECURE

No Known BCC Exposure

RemeGen is a drug innovator, not a CDMO/CRO. No BIOSECURE exposure. No 1260H listing.

1
Tracked Deals
2
Therapeutic Areas
3
Modalities

Overview

RemeGen (荣昌生物) is a clinical-stage biopharmaceutical company that developed disitamab vedotin (Aidixi), a HER2-targeting antibody-drug conjugate (ADC) that became one of the most valuable China-originated ADC assets. The company's $5.6B AbbVie deal for ex-China rights to disitamab vedotin was the largest ADC-specific out-licensing transaction from China, validating the commercial potential of Chinese ADC innovation.

Key Facts

  • AbbVie deal: $5.6B total value ($100M upfront) for disitamab vedotin ex-China rights
  • Disitamab vedotin (Aidixi) — HER2-targeting ADC, approved in China for gastric and urothelial cancers
  • Proprietary ADC platform technology with multiple next-generation candidates in pipeline
  • Dual-listed on Hong Kong and Shanghai STAR Market exchanges

Key Deals

Key licensing and partnership deals for RemeGen.
PartnerDateValueAsset
AbbVie2025$100M upfront / $5.6B totalDisitamab vedotin (HER2 ADC) ex-China rights

Corporate Structure

Dual-listed: Hong Kong (9995) and Shanghai STAR Market (688331). Founded by Dr. Fang Jianmin (房健民). Operating subsidiaries in Yantai and Shanghai.